Display options
Cite
Suman RK, Borde MK, Mohanty IR, et al. Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res. 2016;10(3):FF13-8doi: 10.7860/JCDR/2016/15794.7459.
Suman, R. K., Borde, M. K., Mohanty, I. R., Maheshwari, U., & Deshmukh, Y. A. (2016). Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. Journal of clinical and diagnostic research : JCDR, 10(3), FF13-8. https://doi.org/10.7860/JCDR/2016/15794.7459
Suman, Rajesh Kumar, et al. "Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction." Journal of clinical and diagnostic research : JCDR vol. 10,3 (2016): FF13-8. doi: https://doi.org/10.7860/JCDR/2016/15794.7459
Suman RK, Borde MK, Mohanty IR, Maheshwari U, Deshmukh YA. Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res. 2016 Mar;10(3):FF13-8. doi: 10.7860/JCDR/2016/15794.7459. Epub 2016 Mar 01. PMID: 27134894; PMCID: PMC4843280.
Copy Download .nbib Format: NLM
Share it on

J Clin Diagn Res. 2016 Mar;10(3):FF13-8. doi: 10.7860/JCDR/2016/15794.7459. Epub 2016 Mar 01.

Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction.

Journal of clinical and diagnostic research : JCDR

Rajesh Kumar Suman, Manjusha K Borde, Ipseeta Ray Mohanty, Ujwala Maheshwari, Y A Deshmukh

Affiliations

  1. Tutor, Department of Pharmacology, MGM Medical College , Navi Mumbai, India .
  2. Professor, Department of Pharmacology, MGM Medical College , Navi Mumbai, India .
  3. Professor, Department of Pathology, MGM Medical College , Navi Mumbai, India .
  4. Professor and Head, Department of Pharmacology, MGM Medical College , Navi Mumbai, India .

PMID: 27134894 PMCID: PMC4843280 DOI: 10.7860/JCDR/2016/15794.7459

Abstract

INTRODUCTION: Berberine, an isoquinoline alkaloid isolated from the Berberis aristata, has been shown to display a wide array of pharmacological activities (hypoglycaemic and hypolipidemic).

AIM: The present study was designed to investigate whether these pharmacological properties translate into the cardioprotective effects of Berberine in the setting of diabetes mellitus.

MATERIALS AND METHODS: Necessary approval from the Institutional Animal Ethics Committee was taken for the study. Experimental diabetes was produced with single dose of Streptozotocin (STZ): 45mg/kg ip and myocardial infarction was induced by administering Isoproterenol (ISP): 85mg/kg, sc to rats on 35(th) & 36(th) day. After the confirmation of diabetes on 7(th) day (>200mg/dl), Berberine (100 mg/kg) was administered orally to experimental rats from day 8 and continued for 30 days thereafter. Various anti-diabetic (Glucose, HbA1c), cardioprotective (CPK-MB), metabolic (lipid profile), safety {liver function (SGPT, kidney function (Creatinine)} and histopathological indices of injury were evaluated in Healthy Control, Diabetic Control and Berberine treated groups.

RESULTS: Administration of STZ-ISP resulted in a significant decrease in body weight (p<0.001), diabetic changes (increase in blood glucose, HbA1c), cardiac injury (leakage of myocardial CPK-MB), altered lipid profile, SGPT, creatinine levels (p<0.001) in the diabetic control group rats as compared to healthy control. Berberine treatment demonstrated significant antidiabetic as well as myocardial salvaging effects as indicated by restoration of blood glucose, HbA1c and CPK-MB levels (p<0.001) compared to diabetic control group. In addition, Berberine favourably modulated the lipid parameters (total cholesterol, triglycerides, HDL, LDL). Subsequent to ISP challenge, histopathological assessment of heart, pancreas and biochemical indices of injury confirmed the cardioprotective effects of Berberine in setting of diabetes. In addition, Berberine was found to be safe to the liver and kidney.

CONCLUSION: Berberine treatment produced myocardial salvaging effects in the setting of diabetes challenged with ISP induced myocardial necrosis. Cardioprotection may be attributed to anti-diabetic and hypolipidemic activities.

Keywords: Berberis aristata; Cardioprotective effects; DPP-IV Inhibitor; Isoproterenol

References

  1. Indian J Exp Biol. 1991 Sep;29(9):837-40 - PubMed
  2. Diabetes Obes Metab. 2014 Jan;16(1):48-56 - PubMed
  3. Acta Pharmacol Sin. 2004 Apr;25(4):496-502 - PubMed
  4. Virchows Arch A Pathol Anat Histol. 1982;397(1):83-91 - PubMed
  5. Biol Pharm Bull. 2007 Nov;30(11):2120-5 - PubMed
  6. J Auton Pharmacol. 2001 Feb;21(1):15-21 - PubMed
  7. Endocrinol Nutr. 2012 Jan;59(1):1-8 - PubMed
  8. Nutr Res Rev. 1996 Jan;9(1):241-57 - PubMed
  9. Circulation. 1993 Aug;88(2):750-63 - PubMed
  10. Circulation. 2004 Mar 2;109(8):962-5 - PubMed
  11. J Endocrinol. 2009 Feb;200(2):159-65 - PubMed
  12. Mayo Clin Proc. 2003 Apr;78(4):447-56 - PubMed
  13. Chem Biol Interact. 2014 Aug 5;219:211-20 - PubMed
  14. Evid Based Complement Alternat Med. 2014;2014:849783 - PubMed
  15. Endocrinology. 2003 Jun;144(6):2242-52 - PubMed
  16. Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):142-8 - PubMed
  17. Am J Physiol. 1994 Mar;266(3 Pt 1):E459-66 - PubMed
  18. Metabolism. 2010 Feb;59(2):285-92 - PubMed
  19. World J Cardiol. 2010 Apr 26;2(4):71-7 - PubMed
  20. ISRN Endocrinol. 2011;2011:519371 - PubMed
  21. Asian Pac J Trop Biomed. 2014 May;4(Suppl 1):S429-35 - PubMed
  22. J Enzyme Inhib Med Chem. 2009 Oct;24(5):1061-6 - PubMed
  23. J Int Med Res. 2011;39(5):1720-7 - PubMed
  24. Endocr J. 2010;57(5):423-30 - PubMed
  25. Chin Med. 2010 Sep 18;5:33 - PubMed
  26. Gastroenterology. 2011 Jul;141(1):150-6 - PubMed

Publication Types